Your session is about to expire
← Back to Search
VTX958 for Moderate to Severe Psoriasis (Serenity PsO Trial)
Serenity PsO Trial Summary
This trial will test if a daily oral drug is safe and effective for treating moderate-severe psoriasis. 200 people will take the drug, or a placebo, for 4 months.
Serenity PsO Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSerenity PsO Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Serenity PsO Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have used certain skin medications for psoriasis in the past two weeks.You have had plaque psoriasis for at least 6 months before the screening visit.You have immune-related conditions like psoriatic arthritis, active uveitis, or inflammatory bowel disease that need strong medication to manage.You have a specific type of psoriasis or psoriasis caused by a medication.You have had PUVA treatment within the past 4 weeks before the start of the study.You have taken a medication that is still being tested or has not been approved yet, called a TYK2 inhibitor.You have taken certain medications that can affect psoriasis within the last 4 weeks.You have had UVB phototherapy or excimer laser treatment within the past 4 weeks.Your psoriasis has been the same for at least 3 months before screening.You have a moderate to severe case of plaque psoriasis, as determined by specific scores given by the doctor.You have psoriasis that covers at least 10% of your body.
- Group 1: VTX958 Dose A
- Group 2: VTX958 Dose B
- Group 3: VTX958 Dose C
- Group 4: VTX958 Dose D
- Group 5: Placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the dosage of VTX958 D been officially sanctioned by the Food and Drug Administration?
"As VTX958 Dose D is currently in a Phase 2 trial, the safety of this medication has been judged to be at level 2 due to some evidence from clinical tests but no data indicating its efficacy."
What is the extent of this research project's presence in urban areas?
"Presently, recruitment is taking place at 5 distinct sites. These centres are found in Portland, Indianapolis and Hot Springs as well as two other locations. It's recommended that prospective patients select the nearest medical centre to reduce their need to travel if they decide to join this trial."
Does this experiment have any available openings for participants?
"Affirmative. Clinicaltrials.gov has evidence that this medical experimentation is actively enrolling participants and was published on November 17th 2022, with the most current update made on December 8 of the same year. 200 subjects are needed from 5 distinct locations for this research project."
How many individuals are participating in this clinical trial?
"Affirmative. According to clinicaltrials.gov, the trial has been open since November 17th 2022 and was last modified on December 8th of the same year; seeking 200 participants from 5 different healthcare facilities."
What objectives are researchers hoping to attain from this medical experiment?
"This clinical trial will measure its primary outcome, Psoriasis Area and Severity Index (PASI) Efficacy at 16 weeks, over a 24 week period. Secondary outcomes include PASI-100 Proportion Achievement at Week 16 , alteration in Body Surface Area (BSA) from baseline by the end of Week 16, and change in Dermatology Life Quality Index (DLQI) scores from pre-trial measurement to completion of the study's sixteenth week."
Share this study with friends
Copy Link
Messenger